Clinical Trials

605 enrolled 14 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 3 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02486718 2026-02-05

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

1,280 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

608 enrolled 22 charts 2 FDA

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT02998528 2026-01-06

CheckMate 816

505 enrolled 17 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02799602 2025-12-04

ARASENS

1,306 enrolled 25 charts 5 FDA

Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT01358877 2025-11-28

APHINITY

4,804 enrolled 45 charts 2 FDA

Breast

Breast Neoplasms

NCT04025879 2025-10-16

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

461 enrolled 18 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT02975934 2025-07-25

TRITON3

405 enrolled 34 charts 3 FDA

Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03493854 2024-06-26

FeDeriCa

500 enrolled 28 charts 3 FDA

Breast

Breast Neoplasms

NCT02564263 2023-03-13

KEYNOTE-181

628 enrolled 27 charts 2 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02569242 2022-07-06

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

419 enrolled 20 charts 3 FDA

Gastrointestinal

Esophageal Neoplasms

NCT00950300 2018-01-23

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer